“Its patent will expire next year, and it will be available as a generic and I will introduce it to the entire public health ...
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...
Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...
God knows what volume they’re actually selling. And who knows? You’re just taking it,” one expert told The Post.
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
The drug, called Mounjaro in the UK and Zepbound in the U.S., would be initially offered to obese people with at least three ...
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...